PROOF Centre to Begin Clinical Validation of Heart Transplant Rejection Liquid Biopsy Test Using the HTG EdgeSeq System, a Next-Generation Sequencing (NGS)-Based Platform
TUCSON, Ariz., Sep 21, 2015 (GLOBE NEWSWIRE via COMTEX) --
HTG Molecular Diagnostics, Inc. HTGM, +3.66% a provider of instruments and reagents for molecular profiling applications, announced it has formed a technology partnership with The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) for an RNA-based liquid biopsy from peripheral blood, utilizing the NGS-based HTG EdgeSeq system. The heart transplant rejection blood test is intended to provide early indication of organ rejection in heart transplant patients, allowing doctors to better monitor and treat patients post-transplant. PROOF Centre is preparing to initiate clinical validation studies for their HTG EdgeSeq-based blood test, beginning at St. Paul's Hospital in Vancouver, Canada.
"The development of this blood test was driven by demand from patients who typically have to undergo at least 12 invasive biopsies per year in the first year post-transplant. Currently, there is no globally accepted, affordable blood test available for monitoring heart transplant patients," says Dr. Bruce McManus, PROOF Centre CEO. "The heart transplant rejection blood test developed by PROOF Centre and deployed on the HTG platform will allow doctors to test patients during this crucial period."
PROOF Centre will also use the HTG EdgeSeq system for organ failure research, clinical trials and the development of gene expression based tests. These tests will stratify patients based on message RNA (mRNA) and microRNA (miRNA) expression in challenging sample types such as PAXgene, formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood. Continue reading.